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Among the available agents for osteoporosis, anti-resorptive drugs do not increase bone formation, whereas anabolic agents do not reduce
bone resorption. Strontium ranelate (SR) uniquely does both, rebalancing bone turnover in favour of bone formation. In the Spinal
Osteoporosis Therapeutic Intervention (SOTI) study, a 4-year trial, SR treatment reduced vertebral fracture risk by 33% (P< 0.001), and
symptomatic vertebral fracture risk by 36% (P< 0.001). SR also significantly improved quality of life as assessed by the Quality-of-Life
Questionnaire in Osteoporosis (QUALIOST) instrument. In the Treatment of Peripheral Osteoporosis Study (TROPOS) study, a 5-year trial,
SR significantly reduced total fracture risk by 20% (29.1 vs 33.9%; P< 0.001), total non-vertebral fracture risk by 15% (18.6 vs 20.9%;
P¼ 0.032) and hip fracture risk by 43% (7.2 vs 10.2%; P¼ 0.036) in the subgroup that is at high risk for hip fracture. Analysis of pooled data
from these two studies found that SR is also safe and effective in patients aged580 years, reducing the risk of vertebral fracture over 5 years
by 31% (P¼ 0.010) and non-vertebral fracture by 26% (P¼ 0.019). Adherence to treatment in the trials exceeded 80%, and the adverse event
profile of SR was similar to that of placebo. Taken together, these long-term findings clearly demonstrate that SR is safe and effective
in reducing both vertebral and non-vertebral (particularly hip) fracture risks for at least 5 years of pre-planned follow-up.
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Introduction
Osteoporosis, whose worldwide incidence is on the increase, is a
disease with potentially devastating consequences. Approximately
1.6 million hip fractures occur every year, and this number
is expected to reach 4.5–6.3 million in 2050. Mortality rates of
20–24% have been reported in the first year after a hip fracture,
and 33% of these individuals are totally dependent or in a nursing
home in the year following a hip fracture [1–3]. It is therefore
essential that safe and effective treatments for osteoporosis
are available. Menopause [4] is characterized by an increase in
osteoclast activity, which markedly outweighs osteoblast activity
[5], leading to an imbalance of bone remodelling in the direction of
bone resorption. A range of therapies are available with proven
reduction of vertebral fracture risk, some of them being
demonstrated as effective on the secondary prevention of hip
fractures [6–9]. Questions have been raised about adherence
rates and long-term safety of all these agents [10].
Currently available anti-resorptive agents, such as bisphos-
phonates, first increase BMD by allowing the filling up of the
remodelling space, then increase secondary mineralization of
existing bone [11]; but they do not increase new bone formation.
Anabolic agents, such as teriparatide, do increase new bone
formation, but also stimulate bone resorption.
Strontium ranelate (SR) is a new oral treatment with a unique
dual mode of action. In vitro, SR both reduces the bone resorption
by osteoclasts and stimulates bone formation by osteoblasts
[12, 13]; and in animal studies, it prevents bone loss and increases
bone strength [14, 15]. In patients treated with SR, bone-specific
alkaline phosphatase (a marker of bone formation) is increased,
whereas C-telopeptide cross-link of type 1 collagen (a marker of
bone resorption) is decreased compared with placebo [16]. This
increase in bone-specific alkaline phosphatase and decrease in
serum C-telopeptide cross-link of type 1 collagen were confirmed
over 4 years in the extension of the Spinal Osteoporosis
Therapeutic Intervention (SOTI) trial [17]. Thus, the net effect
of SR is to balance bone remodelling in favour of bone formation
[18]. The long-term clinical safety and efficacy of SR have been
evaluated in two large multinational Phase III randomized clinical
trials involving over 6000 postmenopausal women with
osteoporosis.
Long-term efficacy of SR: reductions in fracture risk
The SOTI trial randomized 1649 postmenopausal women with
osteoporosis and at least one confirmed prior osteoporosis-related
vertebral fracture to receive either SR 2 g/day or placebo for
4 years. In this study, SR treatment reduced the risk of vertebral
fracture by 33% (P< 0.001) and risk of symptomatic vertebral
fracture by 36% (P< 0.001) after 4 years compared with pla-
cebo [17], continuing the pattern of the results seen at 3 years
[16]. Non-vertebral fracture incidence was similar in the two
groups [17].
The Treatment of Peripheral Osteoporosis Study (TROPOS)
study, focusing on non-vertebral fractures, randomized 5091 post-
menopausal women to receive either placebo or SR 2 g/day for
5 years. The findings of the TROPOS study at 5 years, which
continues the pattern seen at 3 years [19], have recently been
published [20]. Relative to placebo, at 5 years, SR significantly
reduced total fracture risk by 20% (29.1 vs 33.9%; P< 0.001),
the risk of total non-vertebral fracture by 15% (18.6 vs 20.9%;
P¼ 0.032), the risk of major non-vertebral fracture by 18% (14.8
vs 16.9%; P¼ 0.025) and the risk of vertebral fracture by 24%
(20.8 vs 24.9%; P< 0.001) [20]. The percentage of overall patients
experiencing a hip fracture was 5.5% in the SR group and 5.9% in
the placebo group. The risk of hip fracture was decreased by
43% (7.2 vs 10.2%; P¼ 0.036) in the 1128 patients at high
risk for hip fracture.
Taken together, these long-term results from the SOTI and
TROPOS trials clearly demonstrate the long-term efficacy of SR
in reducing both vertebral and non-vertebral fracture risks.
Notably, SR is the first osteoporosis treatment with efficacy
over 5 years demonstrated in a pre-planned placebo-
controlled clinical trial. A summary of 5-year data on fracture
risk is shown in Fig. 1 [20, 21].
In comparison, bisphosphonates do not demonstrate the
same benefits. In the Fracture Invention Trial 2, alendronate
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significantly reduced the risk of vertebral fracture over 4 years by
44% and of clinical fracture (all kinds) by 36%. However, this
result on clinical fractures was observed only in a subgroup of
patients with established osteoporosis (T-score >2.5 S.D.). No
reduction was observed among women with higher BMD [22].
Furthermore, there were no fracture data available with alendro-
nate over 5 years.
In a small extension study (265 patients) over 5 years of
the Vertebral Efficacy With Risedronate Trial (VERT), risedro-
nate significantly reduced the risk of new vertebral fracture by
59% in 4 and 5 years [23]. However, no effect on non-vertebral
fractures with risedronate has been reported over 4 and 5 years
[23]. Two other bisphosphonates available in most countries,
ibandronate and zoledronate, have no long-term data.
A 12-month extension of the Multiple Outcomes of Raloxifene
Evaluation (MORE) showed that the 4-year cumulative risk
reduction for vertebral fractures was 36% with raloxifene
60mg/day and 43% with raloxifene 120mg/day. However, the
non-vertebral fracture risk was not significantly reduced with
raloxifene over 4 years [24]. No data are available for teriparatide
over the long term (in fact, no data over >21 months of use).
Long-term efficacy of SR: improvement in BMD
After 4 years, patients in the SOTI trial who had received SR had
increased BMD, whereas those in the placebo group lost BMD;
the differences between SR and placebo groups had grown to
14.6% for lumbar spine BMD, 8.7% for femoral neck and 9.8%
for total hip (all P< 0.001). At the 4-year point, subjects in
the SOTI trial who had been receiving SR (n¼ 572) were
re-randomized in a 1 : 1 ratio to either continue SR treatment
(n¼ 288) or switch to placebo (n¼ 284) for the fifth year, and
those who had been receiving placebo (n¼ 577) were started on
SR. During this fifth year, lumbar spine BMD (the primary out-
come variable for this phase of the study) increased by a mean of
1.2% (P< 0.001) in the continuous SR group and by 5.3%
(P< 0.001) in the group that had switched from placebo to SR,
but declined significantly by 3.2% (P¼ 0.002) in the group
that had switched from SR to placebo. The former two groups
did not differ significantly with respect to vertebral fracture
incidence during the fifth year (6.9 vs 8.9%, respectively;
P¼ 0.463). Furthermore, changes in BMD at the femoral neck
and total hip followed a pattern similar to those for lumbar
spine BMD [17].
It is known that strontium has an increased X-ray absorption
compared with calcium, amplifying BMD measurement by 50%
[16, 25]. In the TROPOS study, BMD at the lumbar spine, femoral
neck and total hip continued to increase throughout the 5-year
study period in the SR group, but not the placebo group (Fig. 2).
During the last 2 years of the study, SR-treated patients increased
their mean BMD by 4.9% at the lumbar spine, 1.8% at the
femoral neck and 2% at the total hip relative to placebo (all
P< 0.001), for total between-group differences over the 5-year
study period of 20.2, 11.3 and 14.1%, respectively (all P< 0.001;
Fig. 2) [20]. These data have a strong clinical implication, as
increases in hip BMD produced by SR are directly correlated
with clinical protection against vertebral and hip fractures [26].
Efficacy of SR treatment up to 8 years
After the 5-year double-blind study period had ended, the subjects
in the TROPOS and SOTI study were offered inclusion in a 3-year
open-label extension for a total follow-up of 8 years; 893 patients
received SR for the entire 8-year period. During the 3-year
open-label phase, lumbar BMD increased by a mean of 4.5%
(P< 0.001); the increase over the whole 8-year interval was
also significant (P< 0.001). The incidence of both vertebral and
FIG. 2. Evolution of BMD at lumbar spine, femoral neck and total hip in the
TROPOS study (5-year data). Reproduced from Ref. [20] with permission of
John Wiley & Sons. *P<0.001.
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FIG. 1. Efficacy of SR in reducing vertebral and non-vertebral fracture risk
over 5 years. *Lumbar and femoral neck BMD T-score 42.4. Adapted from
Refs [20, 21].
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non-vertebral fractures was relatively constant in the SR-
treated women over the entire 8-year period, despite increased
fracture risk due to increasing age. The cumulative incidences of
any osteoporotic fractures during the first 3 and last 3 years of
the studies are shown in Fig. 3. The tolerability of SR over 8 years
of treatment was similar to that observed in both the SOTI and
TROPOS trials [27].
In comparison, after 7 years of treatment in 164 women,
risedronate demonstrated a similar incidence of fractures during
the 6–7 years as compared with the 4–5 years [28]. Ten years of
continuous treatment with alendronate compared with 5 years
treatment with alendronate followed by placebo in the Fracture
Intervention Trial Long-term Extension showed a significant
further reduction of clinical vertebral fractures, but not of the
other fractures [29]. Treatment with 10mg of alendronate daily
for 10 years produced a gradual increase in BMD at the spine,
the trochanter and the femoral neck, as compared with baseline
values [30].
Efficacy of SR in specific populations
Elderly patients
Women aged 580 years account for 25–30% of all fragility
fractures seen in the community, because both osteoporosis and
falls are frequent in this population. Yet, there are few data on the
efficacy of osteoporosis treatment in these patients. Therefore, the
efficacy of SR in this population was explored using pooled data
from 1488 women aged 80–100 years, who were included in the
SOTI and TROPOS trials. This was a frail population with osteo-
porosis, with a mean age of 83.5 years and a mean femoral neck
BMD T-score of 3.3. Half had already suffered at least one prior
vertebral fracture and a third had had at least one non-vertebral
fragility fracture (Table 1) [31].
After 1 year, compared with placebo, SR significantly reduced
the risk of vertebral fracture by 59% (3.5 vs 8.3%; P¼ 0.002),
non-vertebral fracture by 41% (4 vs 6.8%; P¼ 0.027) and
symptomatic fracture by 37% (6.4 vs 9.9%; P¼ 0.012). The
corresponding risk reductions after 3 years were 32 (19.1 vs
26.5%; P¼ 0.013), 31 (14.2 vs 19.7%; P¼ 0.011) and 22% (19.1
vs 22%; P¼ 0.040), respectively. In addition, SR decreased major
non-vertebral fracture incidence and risk by 37% after 3 years
(11.5 vs 17.7%; P¼ 0.003). The incidence of hip fractures was
lower in the SR group after 3 years, although not significantly
reduced (5.2 vs 7.4%; P¼ 0.112). SR was well tolerated, and its
safety profile did not differ significantly from that seen in younger
patients. After 5 years, SR had reduced the risk of a vertebral
fracture by 31% (P¼ 0.010) and non-vertebral fracture by 26%
(P¼ 0.019; Fig. 4) [21].
Patients after long-term bisphosphonate treatment
Is SR an option for patients who remain at high fracture risk
despite long-term treatment with bisphosphonates? One recent
study involved 15 such patients whose bisphosphonate treatment
(mean duration 32 months) had been discontinued due to lack of
efficacy or poor tolerability. Paired transiliac crest biopsies taken
at baseline and after 12 months of treatment with SR (n¼ 10) were
analysed. After 12 months, bone volume (as measured by bone
volume to tissue volume), bone formation (as measured by the
ratio of osteoid surface to bone surface), trabecular thickness
and trabecular interconnections had all significantly increased,
whereas osteoclast number remained low and unchanged. These
findings suggest that in patients who previously took bisphospho-
nate treatment, SR can re-stimulate bone remodelling even after
long-term suppression of bone turnover [32].
Effect of SR on quality of life
With its related pain, deformity and dependence, osteoporosis has
a highly negative impact on quality of life. The Quality-of-Life
Questionnaire in Osteoporosis (QUALIOST), a supplement to
the generic Medical Outcomes Study Short-Form Health Survey
(SF-36) [33], is a validated 23-item instrument specifically directed
to the physical and emotional aspects of osteoporosis-related
quality of life; a lower score indicates a better quality of life
[34]. In the SOTI study, 1250 patients were assessed every
TABLE 1. Baseline characteristics of women aged 80–100 years in the SOTI
and TROPOS trials
SR, n¼739 Placebo, n¼749
Age, years 83.5 3 83.52.9
Time since menopause, years 35.3 6.1 35.46.4
Patients with one or more prevalent, % 46.4 51.4
Vertebral fractures, % 37.1 35.1
Non-vertebral fractures, %
Lumbar spine BMD T-score 2.7 1.7 2.81.7
Femoral neck BMD T-score 3.3 0.7 3.30.7
Duration of exposure to treatment, days 952669 970659
Adapted from Ref. [31] with permission of the American Society for Bone and Mineral
Research.
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6 months for 4 years using both the SF-36 and the QUALIOST.
SR treatment had no significant effects on SF-36 summary
scores. However, after 3 years, treatment with SR significantly
improved emotional, physical and global QUALIOST scores
(global P¼ 0.016; emotional P¼ 0.019; and physical P¼ 0.032)
compared with placebo. Patients reported having fewer negative
feelings and disease-related worries (falling, becoming a burden,
concerns about ageing or physical appearance), as well as reduced
pain and improved mobility [35].
After 4 years, mean QUALIOST global scores had improved
from baseline by 0.06 in the SR group and deteriorated by 1.92 in
the placebo group (P¼ 0.020; Fig. 5). This divergence in
QUALIOST total scores is clinically significant, surpassing as it
does the difference between scores of patients with and without
one new osteoporotic fracture. Both physical and emotional
dimensions were also improved significantly by SR compared
with placebo. A total of 14.6% of the SR patients and 11.2%
of the placebo patients reported being free of back pain
(P¼ 0.005) [17].
Adherence to treatment with SR
Adherence to osteoporosis treatment is often relatively poor;
among the most often cited reasons are experiencing or fearing
side effects and lacking the motivation to persevere with a
preventive treatment [35]. In the two Phase III clinical trials of
SR, rates of adherence to treatment exceeded 80%, attesting to the
tolerability and ease of administration of this agent. In SOTI,
adherence rates were 83% in the SR and 85% in the placebo
group after 3 years [16]. The mean adherence rate in TROPOS
was 82% in both treatment groups after 3 years [19] and 82% after
5 years [20]. This level of compliance compares favourably with
those obtained with other osteoporosis drugs over 3 years: in
the FIT trial: alendronate 81.3%, placebo 82.5%; VERT trial:
risedronate 60%, placebo 55%; and in MORE trial: raloxifene
78%, placebo 75% [22, 36, 37]. In a prospective observational
cohort study including 13 078 patients, >80% of them were con-
tinuing therapy with SR 12 months after the inclusion [38].
Safety
The overall adverse event profile of SR in the two Phase III multi-
national trials—including the incidence of adverse events, serious
adverse events and discontinuations due to adverse events—was
similar to that of placebo. Most adverse events were mild and
transient; the most frequent were nausea (6.6 vs 4.3%) and
diarrhoea (6.5 vs 4.6%), and the main adverse event causing
discontinuation was nausea (2.2% in the SR group vs 1.3% in the
placebo group). Transient changes included decrease in serum
calcium and parathyroid hormone levels and increase in
serum creatinine kinase and serum phosphorus levels; none
was clinically relevant [16, 19, 34, 39]. No new safety issues
regarding SR have emerged in the latter years of the SOTI and
TROPOS trials, or in the open-label 3-year extensions of either
trial [27].
The tolerability of SR was also confirmed in a pre-specified
safety analysis of pooled data from participants in SOTI and
TROPOS, who were aged 580 years. Again, the most frequent
adverse events were gastrointestinal (nausea, diarrhoea and
constipation). Serious adverse events, discontinuations caused by
adverse events and deaths were all seen with similar frequency in
the SR and placebo groups [30].
During post-marketing surveillance, isolated cases of hyper-
sensitivity syndrome or drug rash with eosinophilia and systemic
symptoms have been reported. The clinical manifestations (skin
reaction, fever and systemic findings, hypereosinophilia, hepatic
and renal abnormalities) typically occur within 2–6 weeks after
initiating the therapy. The mechanism has not been elucidated.
Even though this syndrome has been very rarely reported
(16/570 000 patient-years), the treatment should be discontinued
permanently in case of skin rash.
The incidence of venous thromboembolism (VTE) was similar
in both treatment groups in the individual trials SOTI and
TROPOS, but the difference between SR and placebo groups
reached statistical significance [0.9 vs 0.6%; odds ratio
(OR)¼ 1.4] in the pooled analysis. The two treatment groups
were not balanced with regard to proportion of subjects with a
history of VTE events. When these subjects were excluded from
the analysis, there was no statistical difference in treatment-
emergent VTE events between the two treatment arms [34].
It is also of interest that according to data from the large
British General Practice Research Database [40], individuals with
osteoporosis have an elevated risk of VTE compared with those
without the condition (5.6 vs 3.2 cases per 1000 patient-years; age-
adjusted relative risk (RR)¼ 1.42; P¼ 0.007). In this database, the
risks of VTE among patients taking either SR or alendronate are
equivalent, and not significantly different from the risk in the
population with untreated osteoporosis (RR¼ 1.09; P¼ 0.773 for
SR and RR¼ 0.92; P¼ 0.646 for alendronate) [41, 42].
Conclusion
There is an increasing demand for osteoporosis treatments with
demonstrated long-term safety and efficacy. SR has a dual mode
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of action that is more physiological than those of
anti-resorptive (such as bisphosphonates) or anabolic agents
(such as PTH), since it both increases bone formation and
decreases bone resorption. Longer term clinical trial data demon-
strate that SR continues to increase BMD and reduce the
incidence of both vertebral and non-vertebral (particularly hip)
fractures in osteoporotic women for at least 5 years of pre-planned
follow-up. To date, SR is the only osteoporosis drug that has
demonstrated this level of clinical efficacy over 5 years in
pre-planned placebo-controlled trials. In addition, SR attenuates
bone loss and reduces back pain, thereby improving quality of life.
SR appears to be consistently effective across a wide variety of
patient types, including those with and without predictors of frac-
ture risk, patients with osteopaenia, younger postmenopausal
patients (aged 50–65 years) and elderly patients (aged 580
years). Finally, since osteoporosis requires long-term management
into old age, a good safety and tolerability profile is a prerequisite
for any useful osteoporosis treatment. The consistent broad-
spectrum efficacy, rapid action and favourable safety profile
provide support for SR as a valuable first-line choice in the
pharmacological management of postmenopausal osteoporosis.
Rheumatology key messages
 SR is the first osteoporosis treatment to reduce long-term fracture
risk (SOTI and TROPOS).
 Eight-year follow-up confirms sustained anti-fracture efficacy and
tolerability.
 SR’s efficacy and tolerability are sustained long term in patients
aged >80 years.
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